Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

ClinicalTrials.gov ID: NCT02025907

Public ClinicalTrials.gov record NCT02025907. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo Controlled, 2-arm, Parallel-group, 26-week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin Therapy

Study identification

NCT ID
NCT02025907
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Janssen Research & Development, LLC
Industry
Enrollment
218 participants

Conditions and interventions

Interventions

  • Canagliflozin, 100 mg Drug
  • Canagliflozin, 300 mg Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2014
Primary completion
Aug 31, 2015
Completion
Aug 31, 2015
Last update posted
Oct 30, 2016

2014 – 2015

United States locations

U.S. sites
30
U.S. states
17
U.S. cities
30
Facility City State ZIP Site status
Not listed Montgomery Alabama
Not listed Phoenix Arizona
Not listed Little Rock Arkansas
Not listed Northridge California
Not listed Norwalk California
Not listed Rancho Cucamonga California
Not listed San Ramon California
Not listed Aurora Colorado
Not listed Denver Colorado
Not listed Littleton Colorado
Not listed Cooper City Florida
Not listed Miami Florida
Not listed North Miami Beach Florida
Not listed Atlanta Georgia
Not listed Perry Georgia
Not listed Shawnee Mission Kansas
Not listed Marrero Louisiana
Not listed Metairie Louisiana
Not listed Metarie Louisiana
Not listed Rockville Maryland
Not listed Jackson Mississippi
Not listed Picayune Mississippi
Not listed St Louis Missouri
Not listed Nashua New Hampshire
Not listed Albuquerque New Mexico
Not listed Albany New York
Not listed Arlington Texas
Not listed San Antonio Texas
Not listed Sugarland Texas
Not listed Bountiful Utah

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02025907, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 30, 2016 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02025907 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →